[Effectiveness of acipole in prevention of enteric dysbacteriosis due to antibacterial therapy]

Area of Science:

• Microbiology
• Pharmacology
• Clinical Medicine

Background:

• Antibiotic therapy can lead to adverse effects like dysbacteriosis.
• Dysbacteriosis, an imbalance in gut microbiota, is a common complication of antibacterial treatment.
• Managing dysbiosis is crucial for patient recovery and well-being during antibiotic treatment.

Purpose of the Study:

• To evaluate the efficacy of Acipole in managing antibiotic-induced dysbacteriosis.
• To assess the impact of Acipole on the frequency and severity of dysbiosis in patients receiving antibiotics.
• To determine if Acipole can prevent the clinical manifestations of dysbacteriosis.

Main Methods:

• A study involving 120 patients with acute pneumonia or chronic bronchitis exacerbations treated with antibiotics.
• Patients were divided into two groups: one receiving routine antibiotic therapy, the other receiving antibiotics plus Acipole.
• Fecal samples were analyzed using routine bacteriological examination to assess dysbiosis.

Main Results:

• A high incidence of bacteriologically confirmed dysbiosis was observed in patients receiving antibiotics alone.
• The group treated with antibiotics and Acipole showed a lower frequency and severity of dysbiosis.
• Simultaneous administration of Acipole with antibiotics prevented the development of clinical signs of dysbiosis.

Conclusions:

• Acipole is an effective eubiotic for managing antibiotic-associated dysbacteriosis.
• Combining Acipole with standard antibiotic therapy offers a protective effect against dysbiosis development.
• This approach holds practical importance for improving patient outcomes during antibacterial treatment.